Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in RA with inadequate response to bDMARDs (SELECT-BEYOND)
NCT02706847Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in rheumatoid arthritis (RA), sponsored by AbbVie Inc. Primary endpoints: American College of Rheumatology 20% Response at 12 weeks and Low Disease Activity Based on DAS28(CRP) at 12 weeks. Started Mar 2016; status: completed.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02706847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706847.